Patents by Inventor Steven Mark Dunn
Steven Mark Dunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210061878Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC (SEQ ID NO: 126)-HLA-A*0201, the SLLMWITQC SEQ ID NO: 126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 104 and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: ApplicationFiled: October 5, 2020Publication date: March 4, 2021Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Publication number: 20180371049Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201. the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: ApplicationFiled: August 6, 2018Publication date: December 27, 2018Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Publication number: 20180072788Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3S?1 or slower.Type: ApplicationFiled: September 8, 2017Publication date: March 15, 2018Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Patent number: 9822163Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: GrantFiled: October 12, 2016Date of Patent: November 21, 2017Assignee: ADAPTIMMUNE LIMITEDInventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Publication number: 20170088599Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: ApplicationFiled: October 12, 2016Publication date: March 30, 2017Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Patent number: 9512197Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: GrantFiled: December 14, 2015Date of Patent: December 6, 2016Assignee: ADAPTIMMUNE LIMITEDInventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Publication number: 20160159881Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: ApplicationFiled: December 14, 2015Publication date: June 9, 2016Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Patent number: 9255135Abstract: The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a KD of less than or equal to 1 ?M and/or an off-rate (koff) of 1×10?3 S?1 or slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.Type: GrantFiled: January 3, 2013Date of Patent: February 9, 2016Assignees: Immunocore Limited, Adaptimmune LimitedInventors: Bent Karsten Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy
-
Patent number: 9156903Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: GrantFiled: March 26, 2012Date of Patent: October 13, 2015Assignee: ADAPTIMMUNE LIMITEDInventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Publication number: 20130295063Abstract: The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a KD of less than or equal to 1 ?M and/or an off-rate (koff) of 1×10?3 S?1 or slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.Type: ApplicationFiled: January 3, 2013Publication date: November 7, 2013Inventors: Bent K. Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy
-
Publication number: 20130058908Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: ApplicationFiled: March 26, 2012Publication date: March 7, 2013Inventors: Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Patent number: 8378074Abstract: The present invention provides TCRs having high affinity. The TCR binds to SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 with a KD of less than or equal to 1 ?M and/or an off-rate (koff) of 1×10?3 S?1 or slower using Surface Plasmon Resonance. The TCRs are non-native, isolated or recombinant. The TCRs are useful, either alone, or with a therapeutic agent, for targeting HIV infected cells that present the SLYNTVATL (SEQ ID NO:16)-HLA-A*0201 complex.Type: GrantFiled: March 29, 2006Date of Patent: February 19, 2013Assignee: Immunocore LimitedInventors: Bent Karsten Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy
-
Patent number: 8367804Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: GrantFiled: July 5, 2011Date of Patent: February 5, 2013Assignee: Immunocore LimitedInventors: Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn, Lucy Boulter
-
Patent number: 8143376Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC (SEQ ID NO:126) peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: GrantFiled: May 18, 2005Date of Patent: March 27, 2012Assignee: Immunocore LimitedInventors: Jonathan Michael Boulter, Lucy Boulter, legal representative, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Publication number: 20110262414Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: ApplicationFiled: July 5, 2011Publication date: October 27, 2011Applicant: IMMUNOCORE LIMITEDInventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn, Lucy Boulter
-
Patent number: 8008438Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC (SEQ ID NO:126)-HLA-A*0201, the SLLMWITQC (SEQ ID NO:126) peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumor cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: GrantFiled: August 11, 2010Date of Patent: August 30, 2011Assignee: Immunocore LimitedInventors: Jonathan Michael Boulter, Lucy Boulter, legal representative, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Publication number: 20110038842Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: ApplicationFiled: May 18, 2005Publication date: February 17, 2011Applicant: AVIDEX LIMITEDInventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
-
Publication number: 20110014169Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.Type: ApplicationFiled: August 11, 2010Publication date: January 20, 2011Applicant: IMMUNOCORE LIMITEDInventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn, Lucy Boulter
-
Patent number: 7608410Abstract: A method of increasing the affinity and/or decreasing the off-rate of a given TCR specific for a given target pMHC, comprising creating a plurality of TCRs having an ? chain CDR2 sequence and/or a ? chain CDR2 sequence different from the corresponding CDR2 sequence(s) of the given TCR but having the same ? and ? CDR1 and CDR3 sequences as the given TCR, determining the affinity and/or off-rate of members of said plurality of TCRs for the target pMHC, and selecting one or more members having at least a 10-fold greater affinity for the target pMHC than the given TCR and/or a 10-fold slower off-rate for the target pMHC than the given TCR.Type: GrantFiled: October 7, 2008Date of Patent: October 27, 2009Assignee: Immunocore LimitedInventors: Steven Mark Dunn, Yi Li, Jonathan Michael Boulter, Lucy Boulter, legal representative
-
Publication number: 20090214551Abstract: The present invention provides TCRs having an affinity (KD) of less than or equal to 1 ?M, and/or an off-rate (koff) of 1×10?3S?1 or slower, for the SLYNTVATL-HLA-A*0201 complex provided that when the said TCR is presented by cell and comprises SEQ ID NOS:1 and 2, the cell is not a native T cell. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting HIV infected cells presenting that complex.Type: ApplicationFiled: March 29, 2006Publication date: August 27, 2009Applicant: AVIDEX LTD.Inventors: Bent Karsten Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy